8-K/A: Assertio Holdings to be Acquired by Garda Therapeutics

Assertio Holdings, Inc. announced a definitive agreement to be acquired by Garda Therapeutics for $18 per share in cash, plus a contingent value right, and simultaneously divested its non-Rolvedon assets to Cosette Pharmaceuticals.

Summary

• Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by Garda Therapeutics, Inc. through an all-cash tender offer of $18 per share, totaling $125.1 million.
• In conjunction with the acquisition, Assertio is also divesting its non-Rolvedon assets to Cosette Pharmaceuticals, Inc. for an upfront payment of $35 million plus potential milestone payments.
• The acquisition price represents a significant premium to Assertio's unaffected stock price and 30-day and 60-day volume-weighted average prices.
• The transaction has been unanimously approved by the Boards of Directors of both Assertio and Garda.
• Assertio's Board of Directors recommends that stockholders tender their shares in the offer.
• The deal includes a 20-day "window-shop" period, allowing Assertio to consider superior proposals, with a reduced breakup fee if a superior bid is accepted.
• The closing of the transaction is expected in the second quarter of 2026 and is subject to customary conditions, including the tender of a majority of Assertio's common stock.
• A contingent value right (CVR) will be issued to shareholders, providing potential future payments based on certain milestones related to the Sprix product.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it provides shareholders with a clear path to value realization at a significant premium, although the CVR introduces some uncertainty.

Positives

• The acquisition offers shareholders a significant premium to the unaffected stock price and VWAP.
• The all-cash tender offer provides immediate value realization for Assertio shareholders.
• The transaction has unanimous board approval from both companies.
• A "window-shop" period is included, allowing for the potential of a superior offer.
• The divestiture of non-core assets to Cosette streamlines the business.
• The CVR provides potential upside for shareholders based on Sprix product milestones.

Negatives

• Assertio's common stock will no longer be listed on Nasdaq following the transaction.
• The contingent value right (CVR) introduces uncertainty regarding future payments.
• The strategic review process involved engaging with numerous parties, indicating potential prior challenges or a need for strategic change.
• The divestiture of significant assets to Cosette means Assertio will primarily focus on Rolvedon post-transaction.

Risks

• Failure to satisfy closing conditions, including the tender of a majority of shares.
• The possibility of competing offers emerging during the window-shop period.
• Potential delays in closing due to regulatory or other unforeseen circumstances.
• The risk that the contingent value right milestones may not be achieved, resulting in no additional payments to shareholders.
• The company's sole product post-transaction will be Rolvedon, concentrating business risk.
• Potential difficulties in employee retention due to the transaction announcement and pendency.

Future Outlook

The company is being acquired by Garda Therapeutics in an all-cash transaction, with a simultaneous divestiture of certain assets to Cosette Pharmaceuticals. Post-transaction, Assertio will focus solely on its Rolvedon product.

Management Comments

• "Over the course of this extensive multi-month process, the Board, management, and our advisors have conducted a disciplined and wide-ranging review of our business."
• "We evaluated multiple strategic pathways - including a potential sale of the Company, merger opportunities, monetization of Rolvedon, and continuing as a standalone entity."
• "The Company and its advisors engaged more than 35 counterparties, including both strategic and financial buyers."
• "These transactions provide our shareholders with a certain path to value realization amid a rapidly evolving regulatory, reimbursement, and macroeconomic environment."
• "I would like to sincerely thank everyone involved for the hard work that helped the Company to achieve this outcome."

Industry Context

StockSavvy.ai notes that this transaction reflects ongoing consolidation trends within the pharmaceutical sector, particularly for companies with a focused product portfolio like Assertio's post-divestiture. The inclusion of a CVR is a common mechanism to bridge valuation gaps between buyers and sellers, especially when future product performance is uncertain.

Comparison to Industry Standards

• The $18 per share offer price represents a 34.6% premium to the unaffected stock price on March 20, 2026, and a 46.6% premium to the 30-day unaffected VWAP, which are generally in line with premiums seen in similar-sized pharmaceutical acquisition deals.
• The inclusion of a contingent value right (CVR) tied to Sprix product milestones is a standard practice in the industry to account for potential future upside and risk.
• The $4.8 million termination fee for Assertio is within the typical range for transactions of this size, representing approximately 3.8% of the total cash consideration.
• The 20-day window-shop period is a common feature allowing the target company to solicit superior offers, providing a fiduciary out for the board.

Stakeholder Impact

• Shareholders are expected to benefit from the cash premium and potential CVR payments.
• Employees may face uncertainty regarding future employment and benefits, although the company is providing some transition support.
• Customers and suppliers of Assertio's products may experience changes in business relationships and operational procedures following the acquisition and asset divestiture.

Next Steps

• Garda Therapeutics will commence a tender offer for all outstanding shares of Assertio Holdings.
• Assertio will file a Schedule 14D-9 with the SEC.
• Shareholders are advised to review the tender offer materials and Solicitation/Recommendation Statement when they become available.
• The transaction is expected to close in the second quarter of 2026, subject to customary conditions.

Key Dates

Recommendation

While the acquisition offers a premium, the contingent value right introduces uncertainty about the ultimate value realization. Investors should monitor the tender offer process and the performance of Rolvedon and Sprix to make informed decisions.

Keywords

Assertio Holdings, Garda Therapeutics, Merger Agreement, Tender Offer, Acquisition, Cosette Pharmaceuticals, Asset Sale, Contingent Value Right